cme
Pulmonary Hypertension
Dtsch Arztebl Int 2017; 114: 73-84. DOI: 10.3238/arztebl.2016.0073
; ; ; ; ;
| 1. | Galie N, Humbert M, Vachiery JL, et al.: 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016; 37: 67–119 CrossRef CrossRef CrossRef |
| 2. | Galie N, Humbert M, Vachiery JL, et al.: 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903–75 CrossRef MEDLINE |
| 3. | Hoeper MM, Humbert M, Souza R, et al.: A global view of pulmonary hypertension. Lancet Respir Med 2016; 4: 306–22 CrossRef CrossRef |
| 4. | Hoeper MM, Huscher D, Pittrow D: Incidence and prevalence of pulmonary arterial hypertension in Germany. Int J Cardiol 2016; 203: 612–3 CrossRef MEDLINE |
| 5. | Hoeper MM, Huscher D, Ghofrani HA, et al.: Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 2013; 168: 871–80 CrossRef MEDLINE |
| 6. | Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiery JL: Left ventricular heart failure and pulmonary hypertension. Eur Heart J 2016; 37: 942–54 CrossRef MEDLINE PubMed Central |
| 7. | Opitz C, Hoeper MM, Gibbs JSR, et al.: Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum? J Am Coll Cardiol 2016; 68: 368–78 CrossRef MEDLINE |
| 8. | Cannon JE, Su L, Kiely DG, et al.: Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results from the united kingdom national cohort. Circulation 2016; 133: 1761–71 CrossRefMEDLINE |
| 9. | Bonderman D, Wexberg P, Martischnig AM, et al.: A noninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur Respir J 2011; 37: 1096–103 CrossRef MEDLINE |
| 10. | Olsson KM, Delcroix M, Ghofrani HA, et al.: Anticoagulation and survival in pulmonary arterial hypertension: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). Circulation 2014; 129: 57–65 CrossRef MEDLINE |
| 11. | Ehlken N, Lichtblau M, Klose H, et al.: Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial. Eur Heart J 2016; 37: 35–44 CrossRef MEDLINE PubMed Central |
| 12. | Galie N, Barbera JA, Frost AE, et al.: Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834–44 CrossRef MEDLINE |
| 13. | Pulido T, Adzerikho I, Channick RN, et al.: Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809–18 MEDLINE |
| 14. | Lajoie AC, Lauziere G, Lega JC, et al.: Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med 2016; 4: 291–305 CrossRef |
| 15. | Mandich Crovetto D, Alonso Charterina S, Jimenez Lopez-Guarch C, et al.: Multidetector computed tomography shows reverse cardiac remodeling after double lung transplantation for pulmonary hypertension. Radiologia 2016; 58: 277–82 CrossRef MEDLINE |
| 16. | Tudorache I, Sommer W, Kuhn C, et al.: Lung transplantation for severe pulmonary hypertension-awake extracorporeal membrane oxygenation for postoperative left ventricular remodelling. Transplantation 2015; 99: 451–8 CrossRef MEDLINE |
| 17. | Hoendermis ES, Liu LC, Hummel YM, et al.: Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 2015; 36: 2565–73 CrossRef MEDLINE |
| 18. | Redfield MM, Chen HH, Borlaug BA, et al.: Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309: 1268–77 CrossRef MEDLINE PubMed Central |
| 19. | Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW: A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363: 620–8 CrossRef MEDLINE PubMed Central |
| 20. | Corte TJ, Keir GJ, Dimopoulos K, et al.: Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2014; 190: 208–17 CrossRef MEDLINE PubMed Central |
| 21. | Goudie AR, Lipworth BJ, Hopkinson PJ, Wei L, Struthers AD: Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. The Lancet Respiratory Medicine 2014; 2: 293–300 CrossRef |
| 22. | Raherison C, Girodet PO: Epidemiology of COPD. Eur Respir Rev 2009; 18: 213–21 CrossRef MEDLINE |
| 23. | Madani MM, Auger WR, Pretorius V, et al.: Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2,700 patients. Ann Thorac Surg 2012; 94: 97–103 CrossRef MEDLINE |
| 24. | Pepke-Zaba J, Delcroix M, Lang I, et al.: Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011; 124: 1973–81 CrossRef MEDLINE |
| 25. | Ghofrani HA, D’Armini AM, Grimminger F, et al.: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319–29 CrossRef CrossRef |
| 26. | Simonneau G, D’Armini AM, Ghofrani HA, et al.: Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. Lancet Respir Med 2016; 4: 372–80 CrossRef |
| 27. | Hoeper MM, Madani MM, Nakanishi N, Meyer B, Cebotari S, Rubin LJ: Chronic thromboembolic pulmonary hypertension. The Lancet Respiratory Medicine 2014; 2: 573–82 CrossRef |
| 28. | Galie N, Olschewski H, Oudiz RJ, et al.: Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010–9 CrossRefMEDLINE |
| 29. | Galie N, Rubin L, Hoeper M, et al.: Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093–100 CrossRef |
| 30. | Rubin LJ, Badesch DB, Barst RJ, et al.: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896–903 CrossRef MEDLINE |
| 31. | McLaughlin V, Channick RN, Ghofrani HA, et al.: Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015; 46: 405–13 CrossRef MEDLINE |
| 32. | Galie N, Ghofrani HA, Torbicki A, et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148–57 CrossRef MEDLINE |
| 33. | Galie N, Brundage BH, Ghofrani HA, et al.: Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894–903 CrossRefMEDLINE |
| 34. | Ghofrani HA, Galie N, Grimminger F, et al.: Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330–40 CrossRef CrossRef MEDLINE |
| 35. | Ghofrani HA, Grimminger F, Grunig E, et al.: Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir Med 2016; 4: 361–7 CrossRef |
| 36. | Barst RJ, Rubin LJ, Long WA, et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 1996; 334: 296–302 CrossRef MEDLINE |
| 37. | Olschewski H, Simonneau G, Galie N, et al.: Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322–9 CrossRef MEDLINE |
| 38. | Simonneau G, Barst RJ, Galie N, et al.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800–4 CrossRef MEDLINE |
| 39. | Sitbon O, Channick R, Chin KM, et al.: Selexipag for thetreatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522–33 CrossRef MEDLINE |
| 40. | Olsson KM, Meyer B, Hinrichs J, Vogel-Claussen J, Hoeper MM, Cebotari S: Chronic thromboembolic pulmonary hypertension. Dtsch Arztebl Int 2014; 111: 856–62 VOLLTEXT |
